Stocktoria
Black Diamond Therapeutics, Inc. BDTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-01-30
Black Diamond Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | — | — | — |
| R&D expense | $33.6M | $51.3M | $59.4M | $64.4M | $96.8M |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $22.4M | -$69.7M | -$82.4M | -$91.2M | -$125.6M |
| EPS (diluted) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 |
| Operating cash flow | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M |
| Free cash flow | — | -$62.3M | -$66.8M | -$85.3M | -$102.9M |
| Cash & equivalents | $21.0M | $36.4M | $56.2M | $34.3M | $65.8M |
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M |
| Shareholders' equity | $112.2M | $83.3M | $116.7M | $115.7M | $195.9M |
Source: SEC EDGAR filings · CIK 0001701541 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.